Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2012-04-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10549-012-2035-3PMID 22538770PMCID PMC3885980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• POSTER PRESENTATION Open Access

  2013cited by this paper
• Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

  2011cited by this paper
• Signatures of mutation and selection in the cancer genome

  2010cited by this paper
• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

  2010cited by this paper
• A comprehensive catalogue of somatic mutations from a human cancer genome

  2010cited by this paper
• Diverse somatic mutation patterns and pathway alterations in human cancers.

  2010cited by this paper
• Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

  2010cited by this paper
• Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples

  2009cited by this paper
• The breast cancer somatic 'muta-ome': tackling the complexity

  2009cited by this paper
• COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES

  2009cited by this paper
• Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

  2009cited by this paper
• Common Polymorphism in the Phosphatase PHLPP2 Results in Reduced Regulation of Akt and Protein Kinase C*

  2009cited by this paper
• FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression

  2008cited by this paper
• FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation

  2008cited by this paper
• PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

  2008cited by this paper
• High-throughput oncogene mutation profiling in human cancer

  2007cited by this paper
• The Genomic Landscapes of Human Breast and Colorectal Cancers

  2007cited by this paper
• Patterns of somatic mutation in human cancer genomes

  2007cited by this paper
• MALDI-TOF mass spectrometry

  2004cited by this paper
• Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

  2003cited by this paper

• Breast cancer genomic analyses reveal genes, mutations, and signaling networks

  2024influential citation
• Investigation of BRAF V600E Mutation in Breast Cancer Patients

  2024cites this paper
• Gender-Specific Genetic Predisposition to Breast Cancer: BRCA Genes and Beyond

  2024cites this paper
• Unraveling Biomarker Signatures in Triple-Negative Breast Cancer: A Systematic Review for Targeted Approaches

  2024cites this paper
• Systematic Reversal of Drug Resistance in Cancer

  2024cites this paper
• The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications

  2023cites this paper
• Busting the Breast Cancer with AstraZeneca's Gefitinib

  2023influential citation
• Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach

  2023cites this paper
• Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers

  2023cites this paper
• The Predictive and Prognostic Role of RAS–RAF–MEK–ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets

  2022cites this paper
• The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis.

  2022cites this paper
• Utilization of Advanced Molecular Analyses in Clinical Practice in Lung Cancer: A Country Perspective

  2021cites this paper
• MIG‐6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple‐negative breast cancer

  2021cites this paper
• Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study

  2021cites this paper
• Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

  2021cites this paper
• Drug Screening of Potential Multiple Target Inhibitors for Estrogen Receptor-α-positive Breast Cancer

  2021cites this paper
• NGS-based profiling of key cancer genes in Indian triple-negative breast cancer patients reinforces molecular heterogeneity of the disease

  2021cites this paper
• Oncogenic Mutations in Tumorigenesis and Targeted Therapy in Breast Cancer

  2020cites this paper
• Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

  2020cites this paper
• Mis-annotated multi nucleotide variants in public cancer genomics datasets can lead to inaccurate mutation calls with significant implications

  2020cites this paper
• Triple negative breast cancer – Understanding the clinical implications of heterogeneity

  2020cites this paper
• Loss of Fbxw7 Impairs Development of and Induces Heterogeneous Tumor Formation in the Mouse Mammary Gland

  2020influential citation
• Misannotated Multi-Nucleotide Variants in Public Cancer Genomics Datasets Lead to Inaccurate Mutation Calls with Significant Implications

  2020cites this paper
• Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes

  2019cites this paper
• Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype

  2019cites this paper
• Mutation allele‑specific multiplex PCR for the detection of BRAFV600E mutations in breast carcinomas

  2019cites this paper
• FBXW7 Mutations Promote Cell Proliferation, Migration, and Invasion in Cervical Cancer

  2019cites this paper
• Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters

  2019cites this paper
• Dual Inhibition of the PI3K/Akt and MEK5/ERK5 Pathways for the Treatment of Breast Cancer

  2019influential citation
• Identification of key candidate genes for colorectal cancer by bioinformatics analysis

  2019cites this paper
• EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC

  2019cites this paper
• B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model

  2019cites this paper
• Next-Generation Sequencing Assisted in Establishing the Diagnosis and Treatment for a Chinese Patient With Breast and Lung Multiple Primary Malignancies.

  2018cites this paper
• Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

  2018cites this paper
• Role of ESR Pathway Genes in Breast Cancer: A Review

  2018cites this paper
• The Notch3 Receptor and Its Intracellular Signaling-Dependent Oncogenic Mechanisms.

  2018cites this paper
• Denaturing high‐performance liquid chromatography and principal component analysis for identification of DNA point mutations in breast cancer and lymphoma samples

  2018cites this paper
• Circulating tumour-derived DNA in metastatic soft tissue sarcoma

  2018cites this paper
• Therapeutic landscape in mutational triple negative breast cancer

  2018cites this paper
• Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.

  2018cites this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer

  2017cites this paper
• Mouse Models of Breast Cancer: Deceptions that Reveal the Truth

  2017cites this paper
• Bioinformatic approaches for identifying single nucleotide variants and profiling alternative expression in cancer transcriptomes

  2017cites this paper
• Dual‐functional drug liposomes in treatment of resistant cancers☆

  2017cites this paper
• Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

  2017cites this paper
• Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression

  2017cites this paper
• Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer

  2017cites this paper
• PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer.

  2017cites this paper
• Genomic mutation-driven metastatic breast cancer therapy: a single center experience

  2017cites this paper
• Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy.

  2017cites this paper
• Genome-wide Identification and Analysis of Human and Avian 5'-AMP-Activated Protein Kinase Gamma Subunit Genes

  2017cites this paper
• Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

  2016cites this paper
• KRAS, EGFR AND PIK3CA mutation in triple negative breast carcinomas

  2016cites this paper
• The involvement of heat shock proteins and related molecules in the resistance to therapies in breast and gynecologic cancer

  2016cites this paper
• FBXW7 Pathway Functions as a Promising Therapeutic Target ofCholangiocarcinoma

  2016cites this paper
• Primary salivary duct carcinoma of the lung, mucin-rich variant.

  2016cites this paper
• MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine.

  2016cites this paper
• A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

  2016cites this paper
• AKT1E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

  2016cites this paper
• BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities

  2016cites this paper
• Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer

  2016cites this paper
• Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression

  2016cites this paper
• Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

  2016cites this paper
• Somatic mutations in histiocytic sarcoma identified by next generation sequencing

  2016cites this paper
• Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling

  2016cites this paper
• Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

  2016cites this paper
• MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression.

  2016cites this paper
• BRAF mutation in breast cancer by BRAF V600E mutation-specific antibody

  2016cites this paper
• miR-493 contributes to the proliferation and cell cycle in prostate cancer cells by repressing PHLPP 2

  2016cites this paper
• Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature.

  2015cites this paper
• HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer

  2015cites this paper
• MiR-522 contributes to cell proliferation of human glioblastoma cells by suppressing PHLPP1 expression.

  2015cites this paper
• Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.

  2015cites this paper
• Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome

  2015cites this paper
• New approaches for improving outcomes in breast cancer in Europe.

  2015cites this paper
• Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

  2015cites this paper
• The Epidermal Growth Factor Receptor (EGFR / HER-1) Gatekeeper Mutation T790M Is Present in European Patients with Early Breast Cancer

  2015influential citation
• Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.

  2015cites this paper
• Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

  2015cites this paper
• High-Throughput Mutation Profiling Changes before and 3 Weeks after Chemotherapy in Newly Diagnosed Breast Cancer Patients

  2015cites this paper
• Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing

  2015cites this paper
• Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.

  2015cites this paper
• Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

  2015cites this paper
• Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target

  2015cites this paper
• Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence.

  2015cites this paper
• Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer

  2015cites this paper
• The KRas/MAPK Pathway and Ligand Independent Activation of ERα: Implications for the Treatment of Endometrial Cancer

  2014cites this paper
• Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy

  2014cites this paper
• TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers

  2014cites this paper
• Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes

  2014cites this paper
• Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.

  2014cites this paper
• Present and Future Molecular Testing of Lung Carcinoma

  2014cites this paper
• The Biology and Clinical Development of MEK Inhibitors for Cancer

  2014cites this paper
• Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?

  2014cites this paper
• A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

  2014cites this paper
• A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice NEILVASAN, a ROMANYELENSKY, b KAIWANG, b STACYMOULDER, c HANNAHDZIMITROWICZ, a RONIAVRITSCHER, c BALIANGWANG, c

  2014cites this paper
• Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

  2014cites this paper
• Molecular Pathways Molecular Pathways : PI 3 K Pathway Phosphatases as Biomarkers for Cancer Prognosis and Therapy

  2014cites this paper
• The molecular background of mucinous carcinoma beyond MUC2

  2014cites this paper
• Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

  2014cites this paper